Abstract
The prevalence of diabetes has reached epidemic proportions in the developed world and is expect to increase to 5.4% by 2025. This has resulted in an unprecedented number of patients experiencing the macro- and micro-vascular complications of diabetes, such as renal, retinal, neurological and cardiac dysfunction. Premature coronary artery disease and cardiac failure are vastly overrepresented in the diabetic population, with significant morbidity and mortality. In fact, the rate of cardiac events in patients with diabetes is equivalent to non-diabetic patients with a previous myocardial infarction. Epidemiological evidence, combined with the results of large scale trials blocking the renin-angiotensin system (RAS) have provided data to support the hypothesis that angiotensin II and its interaction with the metabolic changes associated with diabetes mellitus is responsible for the pathogenesis of many of these complications. This review focuses on the role of the RAS and the development of diabetic cardiac disease.
Keywords: RAS, Angiotensin II, hypertension, ACE inhibitor, congestive cardiac failure, aldosterone, angiotensin receptor blocker, TGF β1
Current Pharmaceutical Design
Title: Angiotensin II and the Cardiac Complications of Diabetes Mellitus
Volume: 13 Issue: 26
Author(s): K. A. Connelly, A. J. Boyle and D. J. Kelly
Affiliation:
Keywords: RAS, Angiotensin II, hypertension, ACE inhibitor, congestive cardiac failure, aldosterone, angiotensin receptor blocker, TGF β1
Abstract: The prevalence of diabetes has reached epidemic proportions in the developed world and is expect to increase to 5.4% by 2025. This has resulted in an unprecedented number of patients experiencing the macro- and micro-vascular complications of diabetes, such as renal, retinal, neurological and cardiac dysfunction. Premature coronary artery disease and cardiac failure are vastly overrepresented in the diabetic population, with significant morbidity and mortality. In fact, the rate of cardiac events in patients with diabetes is equivalent to non-diabetic patients with a previous myocardial infarction. Epidemiological evidence, combined with the results of large scale trials blocking the renin-angiotensin system (RAS) have provided data to support the hypothesis that angiotensin II and its interaction with the metabolic changes associated with diabetes mellitus is responsible for the pathogenesis of many of these complications. This review focuses on the role of the RAS and the development of diabetic cardiac disease.
Export Options
About this article
Cite this article as:
Connelly A. K., Boyle J. A. and Kelly J. D., Angiotensin II and the Cardiac Complications of Diabetes Mellitus, Current Pharmaceutical Design 2007; 13 (26) . https://dx.doi.org/10.2174/138161207781662984
DOI https://dx.doi.org/10.2174/138161207781662984 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms of Vascular Calcification and Associated Diseases
Current Pharmaceutical Design Patterns of Adverse Drug Reaction in the Medical Wards of a Teaching Hospital: A Prospective Observational Cohort Study
Current Drug Safety Targeting Adenosine Signaling to Treatment of Diabetic Nephropathy
Current Drug Targets Psychosocial Factors and Diabetes Mellitus: Evidence-Based Treatment Guidelines
Current Diabetes Reviews Hypertriglyceridaemia, Postprandial Lipaemia and Non-HDL Cholesterol
Current Pharmaceutical Design Diabetes-Related Neurological Implications and Pharmacogenomics
Current Pharmaceutical Design Graphical Abstracts
Current Diabetes Reviews Metabolic Enzymes of Helminth Parasites: Potential as Drug Targets
Current Protein & Peptide Science The Association of Very High Hair Manganese Accumulation and High Oxidative Stress in Mongolian People
Current Aging Science Obstructive Sleep Apnea and Stroke
Current Respiratory Medicine Reviews Chemical and Clinical Development of Darinaparsin, a Novel Organic Arsenic Derivative
Anti-Cancer Agents in Medicinal Chemistry Pathophysiological Role and Clinical Significance of Lipoprotein-Associated Phospholipase A<sub>2</sub> (Lp-PLA<sub>2</sub>) Bound to LDL and HDL
Current Pharmaceutical Design Mechanisms of Neurodegeration in Type 2 Diabetes and the Neuroprotective Potential of Dipeptidyl Peptidase 4 Inhibitors
Current Medicinal Chemistry The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design Weight Loss in Older Persons: New Therapeutic Approaches
Current Pharmaceutical Design GST T1, M1, and IRS-1 G972R Genetic Variants Association to Gestational Diabetes Mellitus (GDM) in Egyptian Women: Linkage to Maternal Hyperglycemia
Current Diabetes Reviews Metabolic Syndrome and Its Effect on the Brain: Possible Mechanism
CNS & Neurological Disorders - Drug Targets Recent Advances in Characterization of Impurities - Use of Hyphenated LC-MS Technique
Current Pharmaceutical Analysis GLUT4 Associated Proteins as Therapeutic Targets for Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Glucose Lowering Activity of the Aqueous Extract of Warionia saharae in Normal and Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry